公开(公告)号：EP3385273A1

公开(公告)日：2018-10-10

申请号：EP16870020.1

申请日：2016-12-02

申请人： Xiamen University ,  Xiamen Innovax Biotech Co. , Ltd.

发明人： LI, Shaowei ,  LI, Zhihai ,  SONG, Shuo ,  HE, Maozhou ,  GU, Ying ,  XIA, Ningshao

IPC分类号： C07K14/025 ,  C12N15/37 ,  C12N7/04 ,  A61K39/12 ,  A61P31/20 ,  A61P35/00 ,  A61P17/12

CPC分类号： A61K39/12 ,  C07K14/025 ,  C12N7/04

摘要： Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

公开(公告)号：EP3385274A1

公开(公告)日：2018-10-10

申请号：EP16870021.9

申请日：2016-12-02

申请人： Xiamen University ,  Xiamen Innovax Biotech Co., Ltd.

发明人： LI, Shaowei ,  WANG, Daning ,  LIU, Xinlin ,  LI, Zhihai ,  ZHANG, Jun ,  XIA, Ningshao

IPC分类号： C07K14/025 ,  C12N15/37 ,  C12P21/02 ,  A61K39/12 ,  A61P17/12

CPC分类号： A61K39/12 ,  C07K14/025 ,  C12P21/02

摘要： Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.